» Articles » PMID: 9111064

Post-translational Fate of a Mucin-like Leukocyte Sialoglycoprotein (CD43) Aberrantly Expressed in a Colon Carcinoma Cell Line

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1997 Apr 25
PMID 9111064
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

This paper describes the biosynthesis of L-CanAg, a mucin-like glycoprotein which carries the carcinoma-associated carbohydrate epitope sialyl-Lewis a and is secreted by the colon adenocarcinoma cell line COLO 205. Recently, it has been shown that L-CanAg is a novel glycoform of CD43, a surface sialoglycoprotein normally found only on hematopoietic cells. Immunoprecipitation with alpha-GPEP18, a novel antiserum against the cytoplasmic domain of CD43, detected a transmembrane form of L-CanAg carrying sialyl-Lewis a. Cell surface biotinylation experiments demonstrated the presence of transmembrane L-CanAg at the plasma membrane and that COLO 205, unlike the leukocyte cell line HL-60, contained significant amounts of glycosylated intracellular CD43. Immunoprecipitation of phosphate-labeled COLO 205 cells revealed that membrane-bound L-CanAg, like leukocyte CD43, is a phosphoprotein. Interestingly, both surface- and phosphate-labeled L-CanAg were eluted earlier from a gel filtration column than their unlabeled counterparts, indicating that this method could separate membrane-bound L-CanAg from its soluble form. Immunoprecipitations of pulse-chase-labeled COLO 205 lysates fractionated by gel filtration showed that decrease in membrane-bound L-CanAg was concomitant with an increase in the intracellular soluble form. Together, these data indicate that transmembrane L-CanAg is fully glycosylated and phosphorylated before the extracellular domain is cleaved off and stored inside the cell before exocytosis.

Citing Articles

Targeting CD43 optimizes cancer immunotherapy through reinvigorating antitumor immune response in colorectal cancer.

Li Y, Wang X, Li Y, Wang X, Liao J, Wang Y Cell Oncol (Dordr). 2023; 46(3):777-791.

PMID: 36920728 DOI: 10.1007/s13402-023-00794-w.


Aberrant glycosylation as biomarker for cancer: focus on CD43.

Tuccillo F, de Laurentiis A, Palmieri C, Fiume G, Bonelli P, Borrelli A Biomed Res Int. 2014; 2014:742831.

PMID: 24689054 PMC: 3943294. DOI: 10.1155/2014/742831.


Differential expression of c-kit and CD43 in histological subtypes of adenoid cystic carcinoma of salivary gland.

Ahmed M, Abo-Hager E Saudi Dent J. 2013; 22(1):27-34.

PMID: 23960476 PMC: 3723079. DOI: 10.1016/j.sdentj.2009.12.001.


Tumor cell MUC1 and CD43 are glycosylated differently with sialyl-Lewis a and x epitopes and show variable interactions with E-selectin under physiological flow conditions.

Fernandez-Rodriguez J, Dwir O, Alon R, Hansson G Glycoconj J. 2003; 18(11-12):925-30.

PMID: 12820726 DOI: 10.1023/a:1022208727512.


CD43, a molecule with multiple functions.

Rosenstein Y, Santana A, Pedraza-Alva G Immunol Res. 1999; 20(2):89-99.

PMID: 10580634 DOI: 10.1007/BF02786465.